|本期目录/Table of Contents|

[1]韩晗,李雪敏,王爽,等.噬菌体作抗菌剂使用的安全性评价研究进展[J].江苏农业科学,2017,45(22):18-23.
　Han Han,et al.Research progress of safety evaluation of bacteriophage used as antibacterial agents[J].Jiangsu Agricultural Sciences,2017,45(22):18-23.
点击复制

噬菌体作抗菌剂使用的安全性评价研究进展(PDF)
分享到：

《江苏农业科学》[ISSN:1002-1302/CN:32-1214/S]

卷:
第45卷
期数:
2017年22期
页码:
18-23
栏目:
专论与综述
出版日期:
2017-11-20

文章信息/Info

Title:
Research progress of safety evaluation of bacteriophage used as antibacterial agents
作者:
韩晗1; 2;  李雪敏1;  王爽1;  张体瑶1;  姜金仲1;  王冉2
1.贵州师范学院贵州省生物资源开发利用特色重点实验室，贵州贵阳 550018；
2.江苏省农业科学院省部共建国家重点实验室培育基地/江苏省食品质量安全重点实验室，江苏南京 210014
Author(s):
Han Han; et al
关键词:
噬菌体; 噬菌体治疗; 安全性评价; 毒理性; 内源性噬菌体; 抗菌剂; 动物试验; 人体临床试验
Keywords:
-
分类号:
S852.65
DOI:
-
文献标志码:
A
摘要:
噬菌体因其病毒本质，作抗菌剂使用时其安全性常倍受质疑，为探究与论证噬菌体的安全性，综述了近年来噬菌体相关安全性评价的研究结果。以往研究中，无论是动物试验，还是人体临床试验，均证实噬菌体不会对机体产生明显的副作用，而最新的研究揭示了人体内源性噬菌体的存在及其可能的益生作用。噬菌体的应用被认为安全性较高，对于噬菌体的传统认知，可能将被颠覆与更新，不过仍有必要深入开展更为系统的研究，以及从分子水平上探讨噬菌体对人体细胞可能产生的影响。
Abstract:
-

参考文献/References:

［1］Fauci A S，Marston H D. The perpetual challenge of antimicrobial resistance［J］. The Journal of the American Medical Association，2014，331(18)：1853-1854.
［2］Rosso J Q，Zeichner J A. The clinical relevance of antibiotic resistance：thirteen principles that every dermatologist needs to consider when prescribing antibiotic therapy［J］. Dermatologic Clinics，2016，34(2)：167-173.
［3］Martin M J，Thottahil S E，Newman T B. Antibiotics overuse in animal agriculture：a call to action for health care providers［J］. American Journal of Public Health，2015，105(12)：2409-2410.
［4］Ammar A M，Attia A M，El-Aziz N K A，et al. Class 1 integron and associated gene cassettes mediating multiple-drug resistance in some food borne pathogens［J］. International Food Research Journal，2016，23(1)：332-339.
［5］Clokie M R J，Millard A D，Letarov A V，et al. Phages in nature［J］. Bacteriophage，2011，1(1)：31-45.
［6］Borysowski J，Miedzybrodzki R，Gorski A. Phage therapy：current research and applications［M］. Norfolk：Caister Academic Press，2014：159-187.
［7］Kutter E M，Gvasalia G，Alavidze Z，et al. Biotherapy-history，principles and practice. chapter 8：phage therapy［M］. Berlin：Springer Netherlands，2013：191-231.
［8］Kutter E，de Vos D，Gvasalia G，et al. Phage therapy in clinical practice：treatment of human infections［J］. Current Pharmaceutical Biotechnology，2010，11(1)：69-86.
［9］Tiwari R，Dhama K，Kumar A，et al. Bacteriophage therapy for safeguarding animal and human health：a review［J］. Pakistan Journal of Biological Sciences，2014，17(3)：301-315.
［10］Endersen L，OMahony J，Hill C，et al. Phage therapy in the food industry［J］. Annual Review of Food Science and Technology，2014，5(1)：327-349.
［11］Brüssow H. What is needed for phage therapy to become a reality in western medicine?［J］. Virology，2012，434(2)：138-142.
［12］Weinbauer M G. Ecology of prokaryotic viruses［J］. Fems Microbiology Reviews，2004，28(2)：127-181.
［13］Bergh ，Brsheim K Y，Bratbak G，et al. High abundance of viruses found in aquatic environments［J］. Nature，1989，340(6233)：467-468.
［14］Hyman P，Abedon S T. Bacteriophages in health and disease［M］. Oxfordshire：CABI Publishing，2012.
［15］Bogovazova G，Voroshilova N N，Bondarenko V M. The efficacy of Klebsiella pneumoniae bacteriophage in the therapy of experimental Klebsiella infection［J］. Journal of Microbiology，Epidemiology，and Immunobiology，1991(4)：5-8.
［16］Wang J，Hu B，Xu M C，et al. Use of bacteriophages in the treatment of experimental animal bacteremia from imipenem-resistant Pseudomonas aeruginosa［J］. Intemational Journal of Molecular Medicine，2006，17(2)：309-317.
［17］Biswas B，Adhya S，Washart P，et al. Bacteriophage therapy rescues mice bacteremic from a clinical isolate of vancomycin-resistant Enterococcus faecium［J］. Infection and Immunity，2002，70(1)：204-210.
［18］Oduor J M O，Onkoba W N，Maloba F，et al. Safety and therapeutic efficacy of staphylococcus aureus specific lytic phage against multidrug-resistant S.aureus (MDRSA) in BALB/c mice：a prospective study［J］. International Journal of Infectious Diseases，2016，45：108.
［19］韩晗. 产肠毒素性大肠杆菌噬菌体PK88-4的分离及其抗菌效果与安全性的研究［D］. 南京：南京农业大学，2011.
［20］Tóthová L，Celec P，Bábícˇková J，et al. Phage therapy of Cronobacter-induced urinary tract infection in mice［J］. Medical Science Monitor International Medical Journal of Experimental & Clinical Research，2011，17(7)：173-178.
［21］Sunagar R，Patil S A，Chandrakanth R K. Bacteriophage therapy for Staphylococcus aureus bacteremia in streptozotocin-induced diabetic mice［J］. Research in Microbiology，2010，161(10)：854-860.
［22］Capparelli R，Nocerino N，Iannaccone M，et al. Bacteriophage therapy of Salmonella enterica：a fresh appraisal of bacteriophage therapy［J］. Journal of Infectious Diseases，2010，201(1)：52-61.
［23］Majewska J，Beta W，Lecion D，et al. Oral application of T4 phage induces weak antibody production in the gut and in the blood［J］. Viruses，2015，7(8)：4783-4799.
［24］张辉，王冉，包红朵. 李斯特菌噬菌体体内消长规律及其免疫特性分析［J］. 食品科学，2012，33(21)：169-172.
［25］张红梅，梁梅，刘平，等. 噬菌体的免疫原性及安全性评价［J］. 世界科技研究与发展，2012，34(4)：692-695.
［26］Mai V，Ukhanoova M，Visone L，et al. Bacteriophage administration reduces the concentration of Listeria monocytogenes in the gastrointestinal tract and its translocation to spleen and liver in experimentally infected mice［J］. International Journal of Microbiology，2010：624234.
［27］Chennoufi S，Sidoti J，Bruttin A. In vitro and in vivo bacteriolytic activities of Escherichia coli phages：implications for phage therapy［J］. Antimicrobial Agents and Chemotherapy，2004，48(7)：2558-2569.
［28］Hwang J Y，Kim J E，Song Y J，et al. Safety of using Escherichia coli bacteriophages as a sanitizing agent based on inflammatory responses in rats［J］. Food Science and Biotechnology，2016，25(1)：355-360.
［29］Jaiswal A，Koley H，Ghosh A，et al. Efficacy of cocktail phage therapy in treating Vibrio cholerae infection in rabbit model［J］. Microbes and Infection，2013，15(2)：152-156.
［30］Oliveira A，Sereno R，Nicolau A，et al. In vivo toxicity study of phage lysate in chickens［J］. British Poultry Science，2009，50(5)：558-563.
［31］Carvalho C M，Gannon B W，Halfhide D E，et al. The in vivo efficacy of two administration routes of a phage cocktail to reduce numbers of Campylobacter coli and Campylobacter jejuni in chickens［J］. Bmc Microbiology，2010，10(1)：1-11.
［32］Hammerl J A，Jckel C，Alter T，et al. Reduction of Campylobacter jejuni in broiler chicken by successive application of group Ⅱ and group Ⅲ phages［J］. PLoS One，2014，9(12)：e114785.
［33］Wall S K，Zhang J Y，Rostagno M H，et al. Phage therapy to reduce preprocessing Salmonella infections in market-weight Swine［J］. Applied and Environmental Microbiology，2010，76(1)：48-53.
［34］Callaway T R，Edrington T S，Brabban A，et al. Evaluation of phage treatment as a strategy to reduce Salmonella populations in growing swine［J］. Foodborne Pathogens and Disease，2010，8(2)：261-266.
［35］Bicalho M L S，Machado V S，Nydam D V，et al. Evaluation of oral administration of bacteriophages to neonatal calves：phage survival and impact on fecal Escherichia coli［J］. Livestock Science，2012，144(3)：294-299.
［36］Rozema E A，Stephens T P，Bach S J，et al. Oral and rectal administration of bacteriophages for control of Escherichia coli O157：H7 in feedlot Cattle［J］. Journal of Food Protection，2009，72(2)：241-250.
［37］Bbtech A D，Morale S，Boase S，et al. Safety and efficacy of topical bacteriophage and ethylenediaminetetraacetic acid treatment of Staphylococcus aureus infection in a sheep model of sinusitis［J］. International Forum of Allergy and Rhinology，2014，4(3)：176-186.
［38］张波. 静脉给药的安全性［J］. 医学信息旬刊，2010，5(9)：2454-2455.
［39］Weber-Dbrowska B，Mulczyk M，Górski A. Bacteriophage therapy of bacterial infections：an update of our institutes experience［J］. Archivum Immunologiae et Therapiae Experimentalis，2000，48(6)：547-551.
［40］Midzybrodzki R，Borysowski J，Weber-Dbrowska B，et al. Clinical aspects of phage therapy［J］. Advances in Virus Research，2012，83：73-121.
［41］Borysowski J，Gorski A. Is phage therapy acceptable in the immunocompromised host?［J］. International Journal of Infectious Diseases，2008，12(5)：466-471.
［42］Chanishvili N. A literature review of the practical application of bacteriophage research［M］. New York：Nova Science Publishers，2011：1-292.
［43］Chanishvili N. Phage therapy-history from Twort and dHerelle through Soviet experience to current approaches［J］. Advances in Virus Research，2012，83：3-40.
［44］Bruttin A，Brussow H. Human volunteers receiving Escherichia coli phage T4 orally：a safety test of phage therapy［J］. Antimicrobial Agents and Chemotherapy，2005，49(7)：2874-2878.
［45］Sarker S A，Mccallin S，Barretto C，et al. Oral T4-like phage cocktail application to healthy adult volunteers from Bangladesh［J］. Virology，2012，434(2)：222-232.
［46］Sarker S A，Sultana S，Reuteler G，et al. Oral phage therapy of acute bacterial diarrhea with two coliphage preparations：a randomized trial in children from Bangladesh［J］. EBioMedicine，2016，4：124-137.
［47］Wright A，Hawkins C H，nggrd E E，et al. A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa； a preliminary report of efficacy［J］. Clinical Otolaryngology，2009，34(4)：349-357.
［48］Rhoads D D，Wolcott R D，Kuskowski M A，et al. Bacteriophage therapy of venous leg ulcers in humans：results of a phase I safety trial［J］. Journal of Wound Care，2009，18(6)：237-243.
［49］Merabishvili M，Pirnay J P，Verbeken G，et al. Quality-controlled small-scale production of a well-defined bacteriophage cocktail for use in human clinical trials［J］. PLoS One，2009，4(3)：e4944.
［50］Lang L H. FDA approves use of bacteriophages to be added to meat and poultry products［J］. Gastroenterology，2006，131(5)：820-821.
［51］Górski A，Weber-Dabrowska B. The potential role of endogenous bacteriophages in controlling invading pathogens［J］. Cellular and Molecular Life Sciences，2005，62(5)：511-519.
［52］Letarov A，Kulikov E. The bacteriophages in human- and animal body-associated microbial communities［J］. Journal of Applied Microbiology，2009，107(1)：1-13.
［53］Wenger S L，Turner J H，Petricciani J C. The cytogenetic，proliferative and viability effects of four bacteriophages on human lymphocytes［J］. Vitro，1978，14(6)：543-549.
［54］Dabrowska K，Opolski A，Wietrzyk J，et al. Antitumor activity of bacteriophages in murine experimental cancer models caused possibly by inhibition of beta3 integrin signaling pathway［J］. Acta Virologica，2004，48(4)：241-248.
［55］Dabrowska K，Zembala M，Boratynski J，et al. Hoc protein regulates the biological effects of T4 phage in mammals［J］. Archives of Microbiology，2007，187(6)：489-498.
［56］Dbrowska K，Skaradziński G，Jończyk P，et al. The effect of bacteriophages T4 and HAP1 on in vitro melanoma migration［J］. Bmc Microbiology，2009，9(13)：1-9.
［57］Przerwa A，Kniotek M，Nowaczyk M，et al. Bacteriophages inhibit IL-2 production by human T lymphocytes［C］. Abstracts of the 12th Congress of European Society of Organ Transplantation. Geneva：the 12th Congress of European Society of Organ Transplantation，2005：16-20.
［58］Eriksson F，Culp W D，Massey R，et al. Tumor specific phage particles promote tumor regression in a mouse melanoma model［J］. Cancer Immunology and Immunotherapy，2007，56(5)：677-687.
［59］Eriksson F，Tsagozis P，Lundberg K，et al. Tumor-specific bacteriophages induce tumor destruction through activation of tumor-associated macrophages［J］. Journal of Immunology，2009，182(5)：3105-3111.
［60］Korczak-Kowalska，Wiezbicki G，Borysowski P，et al. T4 phage preparations do not induce the production of IL-6 and TNF-α in human monocytes in vitro［C］. Proceedings of Viruses of Microbes Conference. Paris：Viruses of Microbes Conference，2010：21-25.
［61］Miernikiewicz P，Dbrowska K，Piotrowicz A，et al. T4 phage and its head surface proteins do not stimulate inflammatory mediator production［J］. PLoS One，2013，8(8)：e71036.
［62］DHerelle F. The bacteriophage，its role in immunity［M］. Baltimore：William and Wilkins Publishing，1922：125.
［63］Przerwa A，Zimecki M，S＇witana-Jeleń K，et al. Effects of bacteriophages on free radical production and phagocytic functions［J］. Medical Microbiology and Immunology，2006，195(3)：143-150.
［64］黄雷招. 活性氧簇及其介导的自噬［J］. 医学综述，2012，18(19)：3160-3163.
［65］Borysowski J，Wierzbicki P，Kosowska D，et al. The effects of T4 and A3/R phage preparations on whole-blood monocyte and neutrophil respiratory burst［J］. Viral Immunology，2010，23(5)：541-544.
［66］Miedzybrodzki R，Switala-Jelen K，Fortuna W，et al. Bacteriophage preparation inhibition of reactive oxygen species generation by endotoxin-stimulated polymorphonuclear leukocytes［J］. Virus Research，2008，131(2)：233-242.

相似文献/References:

[1]周路,李建华,王丹,等.有限稀释PCR法筛选噬菌体cDNA文库目标克隆[J].江苏农业科学,2014,42(12):26.
　Zhou Lu,et al.Screening of phage cDNA library target clones by limited dilution PCR method[J].Jiangsu Agricultural Sciences,2014,42(22):26.
[2]雷琎,孙宇杰,于达,等.一种利用噬菌体裂解大肠杆菌Rosetta菌株菌体的方法[J].江苏农业科学,2015,43(09):61.
　Lei Jin,et al.A method of pyrolysis of Escherichia coli Rosetta strain using phage[J].Jiangsu Agricultural Sciences,2015,43(22):61.
[3]吴伟胜,李玉保,王守荣,等.大肠杆菌噬菌体的研究进展[J].江苏农业科学,2015,43(08):8.
　Wu Weisheng,et al.Research progress of Escherichia coli bacteriophage[J].Jiangsu Agricultural Sciences,2015,43(22):8.
[4]杨金玉,郭聃洋,尤金娜·戴·盖,等.噬菌体在食品工业中的应用综述[J].江苏农业科学,2018,46(06):1.
　Yang Jinyu,et al.Application of bacteriophage in food industry：a review[J].Jiangsu Agricultural Sciences,2018,46(22):1.
[5]吕孙建,袁雪梅,刘莉,等.宽谱噬菌体NTHP01的生理特征及噬菌作用[J].江苏农业科学,2019,47(03):132.
　Lü Sunjian,et al.Biological characterization and host-range identification of broad-spectrum bacteriophage NTHP01[J].Jiangsu Agricultural Sciences,2019,47(22):132.
[6]曾祥朋,杨清香.噬菌体在环境耐药基因转移中的作用综述[J].江苏农业科学,2019,47(07):14.
　Zeng Xiangming,et al.Role of phage in transfer of environmental antibiotic resistant genes：a review[J].Jiangsu Agricultural Sciences,2019,47(22):14.
[7]王冉,张莉莉,何涛,等.噬菌体治疗中的免疫问题探讨[J].江苏农业科学,2019,47(16):1.
　Wang Ran,et al.Discussion on immune responses in phage therapy[J].Jiangsu Agricultural Sciences,2019,47(22):1.

备注/Memo

备注/Memo:
收稿日期：2016-05-29
基金项目：国家自然科学基金(编号：31402234)；贵州省学位办项目(编号：2011231)。
作者简介：韩晗(1987—)，男，贵州贵阳人，硕士，讲师，研究方向为食源性病原菌的监测与防控。E-mail：teacherhann@126.com。
通信作者：王冉，博士，研究员，研究方向为食源性病原菌的监测与防控。E-mail：wanran2001@126.com。
更新日期/Last Update: 2017-11-20